Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bexicaserin - Longboard Pharmaceuticals

Next Previous
Drug Profile

Bexicaserin - Longboard Pharmaceuticals

Alternative Names: AN 352; LP-352

Latest Information Update: 11 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Longboard Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Amides; Antiepileptic drugs; Fluorinated hydrocarbons; Small molecules
  • Mechanism of Action 5-HT2C serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Developmental disabilities

Most Recent Events

  • 05 Apr 2025 Efficacy and adverse event data from a phase Ib/IIa PACIFIC trial in Developmental disabilities presented at 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)
  • 04 Apr 2025 Updated efficacy and adverse event data from the phase Ib/IIa PACIFIC in Developmental disabilities released by Longboard Pharmaceuticals
  • 12 Feb 2025 Phase-III clinical trials in Developmental disabilities (In children, In adults, In adolescents, In the elderly) in USA (PO) (NCT06908226)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top